BioSpace News Archive

Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s common stock at an exercise price per share of $17.51, which was the closing price on January 9, 2023.

Optimi Health Corp. is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Company’s Annual General Meeting held January 9, 2023.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its preliminary, unaudited sales for the fourth quarter and year ended December 31, 2022 and worldwide sales outlook for the year ending December 31, 2023.

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2022 financial results.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced its 2023 financial guidance and commented on its outlook for the upcoming year.

Mirum Pharmaceuticals, Inc. announced that on January 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common stock and 12,000 restricted stock units to four new employees under Mirum’s 2020 Inducement Plan.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 and MN-002 for the treatment of scleroderma and/or systemic sclerosis.

Medtronic plc, a global leader in healthcare technology, has been named to the 2023 Rankings of America’s Most JUST Companies by JUST Capital, along with media partner CNBC, for its commitment to serving its employees, customers, communities, the environment, and shareholders.

NKGen Biotech today announced the appointment of Paul Y. Song, MD as Chief Executive Officer (CEO) and Vice Chairman of the Board of Directors, effective January 10, 2023.

Dr. Aysha Khoury is pleased to announce the settlement of her lawsuit and withdrawal of her National Labor Relations Board charge against the Kaiser Permanente Bernard J. Tyson School of Medicine (“KPSOM”).